These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 34105505)
41. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment. Sheervalilou R; Shirvaliloo M; Sargazi S; Bahari S; Saravani R; Shahraki J; Shirvalilou S; Shahraki O; Nazarlou Z; Shams Z; Ghaznavi H Blood Purif; 2022; 51(1):1-14. PubMed ID: 33789273 [TBL] [Abstract][Full Text] [Related]
42. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response). De Santis GC; Calado RT Emerg Infect Dis; 2022 May; 28(5):1083-1084. PubMed ID: 35447061 [No Abstract] [Full Text] [Related]
43. Convalescent plasma for COVID-19 complicated by ARDS due to TRALI. Wang KY; Shah P; Pierce M BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33509890 [TBL] [Abstract][Full Text] [Related]
44. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study. Wu Y; Hong K; Ruan L; Yang X; Zhang J; Xu J; Pan S; Ren L; Chen L; Huang C; Shang Y Virol Sin; 2020 Dec; 35(6):768-775. PubMed ID: 32865701 [TBL] [Abstract][Full Text] [Related]
45. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068 [TBL] [Abstract][Full Text] [Related]
46. A review: Epidemiology, pathogenesis and prospect in developing vaccines for novel Coronavirus (COVID-19). Gupta P Indian J Tuberc; 2021 Jan; 68(1):92-98. PubMed ID: 33641858 [TBL] [Abstract][Full Text] [Related]
47. Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities. Farrugia A Transfus Clin Biol; 2020 Aug; 27(3):167-168. PubMed ID: 32563550 [No Abstract] [Full Text] [Related]
48. Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID-19-An exploratory study. Jaiswal V; Nasa P; Raouf M; Gupta M; Dewedar H; Mohammad H; Al Rais Z; Ali Baqer M; Alsabbah A; Ibrahim Y; Salem M; Shammass D; Marashi M Int J Infect Dis; 2021 Jan; 102():332-334. PubMed ID: 33157287 [TBL] [Abstract][Full Text] [Related]
49. Treatment of immunocompromised COVID-19 patients with convalescent plasma. Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856 [TBL] [Abstract][Full Text] [Related]
50. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples. Anand SP; Prévost J; Richard J; Perreault J; Tremblay T; Drouin M; Fournier MJ; Lewin A; Bazin R; Finzi A Transfusion; 2021 May; 61(5):1377-1382. PubMed ID: 33604922 [TBL] [Abstract][Full Text] [Related]
51. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105 [TBL] [Abstract][Full Text] [Related]
52. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19. Al-Tawfiq JA; Arabi Y Hum Vaccin Immunother; 2020 Dec; 16(12):2973-2979. PubMed ID: 32881641 [TBL] [Abstract][Full Text] [Related]
53. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19. Jin C; Yu B; Zhang J; Wu H; Zhou X; Yao H; Liu F; Lu X; Cheng L; Jiang M; Wu N BMC Infect Dis; 2021 Apr; 21(1):357. PubMed ID: 33863281 [TBL] [Abstract][Full Text] [Related]
54. Convalescent plasma treatment of critically ill intensive care COVID-19 patients. Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412 [TBL] [Abstract][Full Text] [Related]
55. The presence of anti-leucocyte antibodies in the plasma of convalescent women after SARS-CoV-2 infection as a reason for disqualification for plasma therapy - analysis based on a literature review. Wendlocha D; Janusz A; Janusz J; Królewska-Daszczyńska P; Englisz A; Smycz-Kubańska M; Mielczarek-Palacz A Pol Merkur Lekarski; 2021 Jun; 49(291):227-230. PubMed ID: 34218245 [TBL] [Abstract][Full Text] [Related]